Streetbeat News

Price Targets

CRC

B of A Securities analyst Kalei Akamine maintains a Buy rating on California Resources (NYSE:CRC) and raises the price target from $59 to $63.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 9:42 am

ASC

Jefferies analyst Omar Nokta has reiterated a 'Buy' rating on Ardmore Shipping (NYSE:ASC) and raised the price target from $16 to $18.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 9:42 am

SYM

Craig-Hallum analyst Greg Palm maintains a Buy rating on Symbotic (NASDAQ:SYM) and raises the price target from $48 to $61.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 9:41 am

FRLN

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Freeline Therapeutics (NASDAQ:FRLN) and maintained a $15 price target.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 9:41 am

HURN

Barrington Research analyst Kevin Steinke has maintained an Outperform rating on Huron Consulting Gr (NASDAQ:HURN) and raised the price target from $105 to $120.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 9:41 am

AMRC

Craig-Hallum analyst Eric Stine maintains a 'Buy' rating on Ameresco (NYSE:AMRC) and raises the price target from $68 to $73.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 9:41 am

OC

Argus Research analyst Michael Jaffe has maintained a 'Buy' rating on Owens-Corning (NYSE:OC) and raised the price target from $120 to $155.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 9:40 am

ADM

Argus Research analyst David Coleman maintains a Buy rating on Archer-Daniels Midland (NYSE:ADM) and raises the price target from $91 to $95.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 9:40 am

VLY

Valley National Bancorp's stock has been downgraded from Outperform to Market Perform by Hovde Group, which also set a price target of $11. This has led to a decrease in the trading price of the shares.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 9:39 am

TNXP

Alliance Global Partners analyst James Molloy has maintained a 'Buy' rating on Tonix Pharmaceuticals (NASDAQ:TNXP), but lowered the price target from $18 to $8.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 9:39 am